In the management of chronic obstructive pulmonary disorder (COPD), several therapeutic mechanisms have been developed. These therapies include monoclonal antibodies that target pro-inflammatory alarmins and associated cytokine pathways. With continued developments in COPD management, biologic therapies are a promising strategy to achieve treatment goals with promising data showing potential for improving outcomes in patient care.